Clinical characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome
- PMID: 15730921
Clinical characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome
Abstract
Background: Abnormal liver function was found in patients with severe acute respiratory syndrome (SARS). This study was undertaken to explore the clinical characteristics and mechanisms of liver damage.
Methods: The serial laboratory data of liver function test and hepatic histological examination from 168 patients with SARS were retrospectively analyzed.
Results: The abnormalities of serum alanine aminotransferase (ALT) were 52.5%, 71.8%, 85.7% and 85.2%. The average levels of ALT of the patients were 56.07+/-51.57 U/L, 86.46+/-69.93 U/L, 106.69+/-102.50 U/L and 111.32+/-160.24 U/L, and the average levels of serum albumin were 37.25+/-5.37 g/L, 35.82+/-4.74 g/L, 34.49+/-5.04 g/L, and 34.26+/-4.70 g/L, at the day of admission, the first week, second week, and third week after hospitalization, respectively. Significant correlation was not shown among liver damage, blood oxygen saturation (SaO2), degree of fever, and immune functional disorder in this study. Hepatic histological examination of 4 patients demonstrated that non-specific inflammation existed in the liver.
Conclusions: Liver damage of patients with SARS usually occurs in the early stage of the disease with a high occurrence rate and a prolonged profile, which can be characterized by early, obvious decrease of albumin levels and slightly abnormal levels of ALT. The liver damage induced by SARS seems to be caused by SARS virus directly rather than by low SaO2 or high fever. Hepatotoxic drugs may play a role in increasing the severity of liver damage or prolonging the time of liver function recovery.
Similar articles
-
Serum hepatic enzyme manifestations in patients with severe acute respiratory syndrome: retrospective analysis.World J Gastroenterol. 2004 Jun 1;10(11):1652-5. doi: 10.3748/wjg.v10.i11.1652. World J Gastroenterol. 2004. PMID: 15162543 Free PMC article.
-
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.J Hepatol. 2020 Oct;73(4):807-816. doi: 10.1016/j.jhep.2020.05.002. Epub 2020 May 11. J Hepatol. 2020. PMID: 32437830 Free PMC article.
-
[Study on the damage of liver in patients with SARS].Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004 May;16(5):267-70. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004. PMID: 15132787 Chinese.
-
SARS: are we still at risk?JAAPA. 2006 Mar;19(3):48-52, 54. doi: 10.1097/01720610-200603000-00007. JAAPA. 2006. PMID: 16550673 Review. No abstract available.
-
[SARS corona virus--a new dilemma].Med Pregl. 2005 Jan-Feb;58(1-2):43-6. doi: 10.2298/mpns0502043k. Med Pregl. 2005. PMID: 18257204 Review. Serbian.
Cited by
-
COVID-19 and hepatorenal syndrome.World J Gastroenterol. 2022 Oct 21;28(39):5666-5678. doi: 10.3748/wjg.v28.i39.5666. World J Gastroenterol. 2022. PMID: 36338894 Free PMC article. Review.
-
SARS-CoV nucleocapsid protein interacts with cellular pyruvate kinase protein and inhibits its activity.Arch Virol. 2012 Apr;157(4):635-45. doi: 10.1007/s00705-011-1221-7. Epub 2012 Jan 6. Arch Virol. 2012. PMID: 22222284 Free PMC article.
-
COVID-19-induced liver injury in infants, children, and adolescents.World J Clin Pediatr. 2023 Jun 9;12(3):57-67. doi: 10.5409/wjcp.v12.i3.57. eCollection 2023 Jun 9. World J Clin Pediatr. 2023. PMID: 37342451 Free PMC article. Review.
-
Impact of COVID-19 on liver.World J Clin Cases. 2021 Sep 26;9(27):7998-8007. doi: 10.12998/wjcc.v9.i27.7998. World J Clin Cases. 2021. PMID: 34621856 Free PMC article. Review.
-
Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver.Biomed Pharmacother. 2021 Jan;133:111064. doi: 10.1016/j.biopha.2020.111064. Epub 2020 Nov 28. Biomed Pharmacother. 2021. PMID: 33378966 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous